Navigation Links
SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern
Date:4/29/2009

BOTHELL, Wash., April 29 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced plans to release first quarter 2009 financial results on Friday, May 1, 2009, at 8:30 a.m. Eastern. Dr. Bruce S. Morra, President and CEO of SCOLR Pharma, will host the conference call at 11:30 a.m. Eastern, to discuss the Company's results for the quarter.

Shareholders and other interested parties may participate in the conference call by dialing +1 888 713 4217 (domestic) or +1 617 213 4869 (international) and entering access code 55195099, a few minutes before 11:30 a.m. ET on May 1, 2009. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through May 15, 2009, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 86289597. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company whose objective is to combine its formulation expertise and its patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.368.1050 or visit http://www.scolr.com/.

    Contact:
    Investor Relations:
    Cameron Associates
    Kevin McGrath
    212.245.4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor
2. SCOLR Pharma, Inc. Schedules Fourth Quarter 2008 Financial Results Conference Call for March 11, 2009 at 11:30 A.M. Eastern
3. SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
4. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
5. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
6. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
7. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
8. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
9. China Biopharma, Inc. Issues Corporate Information Update
10. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
11. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that two of its ... of bioassays at two upcoming conferences. , At the BEBPA 10th Annual Bioassay ...
(Date:9/25/2017)... ... ... NCPDP Foundation , a 501(c)(3) nonprofit charitable organization ... grant to Johns Hopkins Medicine to address patient safety risk by implementing CancelRx ... a prescription already submitted to a pharmacy. Studies indicate that up to 3% ...
(Date:9/25/2017)... ... September 25, 2017 , ... Lean ... efficiency. The principle of First-Defect-Stop for laboratory weighing is designed to ... the chance to have negative consequences on downstream processes. , If a problem ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... technology-enabled services supporting clinical research, today announces that 30 of its domain ... the drug development lifecycle at upcoming industry conferences and webinars. Drawing on ...
(Date:9/25/2017)... ... September 25, 2017 , ... Ron Norman, CEO of Team ... upper-level executives speaking at a business luncheon today, "It is tantamount to forgetting ... asset to be fully realized and activated by the corporations that recognize their ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Healthcare Conference at the Grand Hyatt hotel in New ... 2017 at 11:40 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology: